Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 29, 2015

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Neurofibroma, PlexiformPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Promyelocytic, AcuteSarcoma

Interventions

DRUG

TURALIO(R)

take oral drug daily for a 28 day cycle

Trial Locations (1)

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH